Why the study?
Heart failure affects over 26 million people worldwide with high morbidity and mortality, and diabetes mellitus is an increasingly prevalent cause.
Do sodium-glucose cotransporter-2 inhibitors improve outcomes in patients with diabetes and heart failure?
Do sodium-glucose cotransporter-2 inhibitors improve outcomes in patients with diabetes and heart failure?
This review highlights the established benefits of SGLT2 inhibitors in HFrEF while noting that their efficacy in HFpEF requires further investigation.
Introduction: Heart failure (HF) affects over 26 million people worldwide and is associated with high morbidity and mortality. Diabetes mellitus (DM) is a common cause of HF in current clinical practice. In recent years, the prevalence of DM has increased considerably, with an estimated 439 million adults worldwide projected to be affected by the year 2030. The aim: To was evaluate of modern trials in patients with diabetes and heart failure treated by Sodium-glucose cotransporter-2 inhibitors. Materials and Methods: The database from PubMed for the last 10 years has been reviewed. Conclusion: SGLT2i, namely Empagliflozin, has good results in their recovery from patients with HFrEF, but the results of their use in patients with HFpEF are currently questionable and need further study.
No takes yet. Share an insight, caveat, or question.
Herashchenko et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: